Induction of Cell Death by Bifidobacterium infantis DS1685 in Colorectal and Breast Cancers via SMAD4/TGF-Beta Activation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Therapeutic advancements in treatments for cancer, a leading cause of mortality worldwide, have lagged behind the increasing incidence of this disease. There is a growing interest in multifaceted approaches for cancer treatment, such as chemotherapy, targeted therapy, and immunotherapy, but due to their low efficacy and severe side effects, there is a need for the development of new cancer therapies. Recently, the human microbiome, which is comprised of various microorganisms, has emerged as an important research field due to its potential impact on cancer treatment. Among these microorganisms, Bifidobacterium infantis has been shown to significantly improve the efficacy of various anticancer drugs. However, research on the role of B. infantis in cancer treatment remains insufficient. Thus, in this study, we explored the anticancer effect of treatment with B. infantis DS1685 supernatant (BI sup) in colorectal and breast cancer cell lines. Treatment with BI sup induced SMAD4 expression to suppress cell growth in colon and breast cancer cells. Furthermore, a decrease in tumor cohesion was observed through the disruption of the regulation of EMT-related genes by BI sup in 3D spheroid models. Based on these findings, we anticipate that BI sup could play an adjunctive role in cancer therapy, and future cotreatment of BI sup with various anticancer drugs may lead to synergistic effects in cancer treatment.
Abstract
Therapeutic advancements in treatments for cancer, a leading cause of mortality worldwide, have lagged behind the increasing incidence of this disease. There is a growing interest in multifaceted approaches for cancer treatment, such as chemotherapy, targeted therapy, and immunotherapy, but due to their low efficacy and severe side effects, there is a need for the development of new cancer therapies. Recently, the human microbiome, which is comprised of various microorganisms, has emerged as an important research field due to its potential impact on cancer treatment. Among these microorganisms, Bifidobacterium infantis has been shown to significantly improve the efficacy of various anticancer drugs. However, research on the role of B. infantis in cancer treatment remains insufficient. Thus, in this study, we explored the anticancer effect of treatment with B. infantis DS1685 supernatant (BI sup) in colorectal and breast cancer cell lines. Treatment with BI sup induced SMAD4 expression to suppress cell growth in colon and breast cancer cells. Furthermore, a decrease in tumor cohesion was observed through the disruption of the regulation of EMT-related genes by BI sup in 3D spheroid models. Based on these findings, we anticipate that BI sup could play an adjunctive role in cancer therapy, and future cotreatment of BI sup with various anticancer drugs may lead to synergistic effects in cancer treatment.
참고문헌 (34)
- Nagai H, "Cancer prevention from the perspective of global cancer burden patterns", J. Thorac. Dis, 9, pp.448~451 (2017)
- Siddiqui R, "The pivotal role of the gut microbiome in colorectal cancer", Biology(Basel), 11, pp.1642~ (2022)
- Noor A, "Breast cancer metastasis masquerading as primary colon and gastric cancer : A case report", Am. J. Case Rep, 21, pp.e917376~ (2020)
- Arthur JC, "Intestinal inflammation targets cancerinducing activity of the microbiota", Science, 338, pp.120~123 (2012)
- Cheng Y, "The intestinal microbiota and colorectal cancer", Front. Immunol, 11, pp.615056~ (2020)
- Dahmus JD, "The gut microbiome and colorectal cancer : a review of bacterial pathogenesis", J. Gastrointest. Oncol, 9, pp.769~777 (2018)
- Pandey H, "Gut microbiota in colorectal cancer : Biological role and therapeutic opportunities", Cancers(Basel), 15, pp.866~ (2023)
- O'Neill I, "Exploring the role of the microbiota member Bifidobacterium in modulating immune-linked diseases", Emerg. Top. Life Sci, 1, pp.333~349 (2017)
- Underwood MA, "Bifidobacterium longum subspecies infantis : champion colonizer of the infant gut", Pediatr. Res, 77, pp.229~235 (2015)
- Ren Z, "Effect of Bifidobacterium animalis subsp. lactis SF on enhancing the tumor suppression of irinotecan by regulating the intestinal flora", Pharmacol. Res, 184, pp.106406~ (2022)
- Massague J, "TGFbeta signalling in context", Nat. Rev. Mol. Cell Biol, 13, pp.616~630 (2012)
- Valcourt U, "TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition", Mol. Biol. Cell, 16, pp.1987~2002 (2005)
- Gupta S, "EMT : Matter of life or death?", Cell, 164, pp.840~842 (2016)
- David CJ, "TGF-beta tumor suppression through a lethal EMT", Cell, 164, pp.1015~1030 (2016)
- Ryu TY, "Human gut-microbiome-derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer", ISME J, 16, pp.1205~1221 (2022)
- Todorov L, "Etiology and use of the"hanging drop"technique : a review", Pain Res. Treat, 2014, pp.146750~ (2014)
- Chen Q, "S100A2 induces epithelial-mesenchymal transition and metastasis in pancreatic cancer by coordinating transforming growth factor beta signaling in SMAD4-dependent manner", Cell Death Discov, 9, pp.356~ (2023)
- Rojas A, "TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta", Biochim. Biophys. Acta, 1793, pp.1165~1173 (2009)
- Ioannou M, "Smad4 and epithelial-mesenchymal transition proteins in colorectal carcinoma : an immunohistochemical study", J. Mol. Histol, 49, pp.235~244 (2018)
- Maier HJ, "Epithelial-mesenchymal transition in pancreatic carcinoma", Cancers(Basel), 2, pp.2058~2083 (2010)
- Clark AG, "Modes of cancer cell invasion and the role of the microenvironment", Curr. Opin. Cell Biol, 36, pp.13~22 (2015)
- Wang X, "Abnormal aggregation of invasive cancer cells induced by collective polarization and ECM-mediated mechanical coupling in coculture systems", Research(Wash D C), 2021, pp.9893131~ (2021)
- Gopi LK, "Integrative pan cancer analysis reveals epigenomic variation in cancer type and cell specific chromatin domains", Nat. Commun, 12, pp.1419~ (2021)
- Tung KH, "Aggregation of ovarian cancer with breast, ovarian, colorectal, and prostate cancer in first-degree relatives", Am. J. Epidemiol, 159, pp.750~758 (2004)
- Harryman WL, "The cohesive metastasis phenotype in human prostate cancer", Biochim. Biophys. Acta, 1866, pp.221~231 (2016)
- Schuster E, "Better together : circulating tumor cell clustering in metastatic cancer", Trends Cancer, 7, pp.1020~1032 (2021)
- Kandalai S, "The human microbiome and cancer : a diagnostic and therapeutic perspective", Cancer Biol. Ther, 24, pp.2240084~ (2023)
- Algrafi AS, "Microbiota as a new target in cancer pathogenesis and treatment", Cureus, 15, pp.e47072~ (2023)
- Procaccianti G, "Bifidobacterium in anticancer immunochemotherapy : friend or foe?", Microbiome Res. Rep, 2, pp.24~ (2023)
- Wei H, "Antitumor mechanisms of bifidobacteria", Oncol. Lett, 16, pp.3~8 (2018)
- Gomes S, "Microbiota-derived short-chain fatty acids : new road in colorectal cancer therapy", Pharmaceutics, 14, pp.2359~ (2022)
- Son MY, "Anticancer effects of gut microbiota-derived short-chain fatty acids in cancers", J. Microbiol. Biotechnol, 33, pp.849~856 (2023)
- Liu Y, "Microbial metabolites in colorectal tumorigenesis and cancer therapy", Gut Microbes, 15, pp.2203968~ (2023)
- Bernardo G, "The emerging role of the microbiota in breast cancer progression", Cells, 12, pp.1945~ (2023)